Evidence map›Paper›PMID 40245252›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Noninvasive Assessment of β-Secretase Activity Through Click Chemistry-Mediated Enrichment of Neuronal Extracellular Vesicles to Detect Alzheimer's Disease.

Hyoyong Kim, Junseok Lee, Audrey Qian, You-Ren Ji, Ryan Zhang, Qixin Hu, Christopher Kazu Williams, Han-Yu Chuang, Matthew D Smalley, Yaya Xu and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hyoyong KimCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.ORCID https://orcid.org/0000-0002-8931-8298
Junseok LeeCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.ORCID https://orcid.org/0000-0002-3709-1386
Audrey QianCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.
You-Ren JiCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.
Ryan ZhangCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.
Qixin HuCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.
Christopher Kazu WilliamsDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Han-Yu ChuangEximius Diagnostics Corp, Magnify Incubator, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.
Matthew D SmalleyEximius Diagnostics Corp, Magnify Incubator, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.
Yaya XuCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.
Liang GaoCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.
Mary C MayoDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Ting ZhangDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Edwin M PosadasDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Zaldy S TanDepartments of Neurology and Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Harry V VintersDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Keith VosselDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Shino MagakiDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Yazhen ZhuCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.
Hsian-Rong TsengCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA.ORCID https://orcid.org/0000-0003-0942-5905

Funding

The UCLA Center in Early Detection of Liver CancerU01CA230705 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vatche Agopian, Samuel Wheeler French · 2018 to 2026
$6.6M
Clinical Validation Center for Hepatocellular CarcinomaU01CA271887 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI FASIHA KANWAL, JORGE A MARRERO · 2022 to 2026
$4.7M
Non-Invasive Prenatal Diagnostics Based on Circulating TrophoblastsU01EB026421 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PISARSKA, MARGARETA, TSENG, HSIAN-RONG · 2019 to 2023
$4.0M
HCC EV Digital Scoring Assay for assessing treatment response in HCC patientsR01CA253651 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2020 to 2024
$3.3M
Extracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular CarcinomaR01CA255727 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHU, YAZHEN · 2021 to 2025
$3.2M
Integrated analysis of HCC CTCs for Liver Transplant Candidate SelectionR01CA246304 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2020 to 2024
$2.8M
Click Chemistry-Mediated Surface Protein Assay for Quantifying Subpopulations of Hepatocellular Carcinoma-associated Extracellular VesiclesR01CA277530 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vatche Agopian, HSIAN-RONG TSENG · 2023 to 2026
$2.6M
Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular CarcinomaR44CA288163 · NCI · EXIMIUS DIAGNOSTICS CORP · PI CHUANG, HAN-YU, LIU, SEAN XIAO · 2023 to 2025
$2.0M
Novel circulating biomarker digital scores for assessing treatment response in liver cancerK08CA259534 · NCI · CEDARS-SINAI MEDICAL CENTER · PI YANG, JU DONG · 2022 to 2024
$807k
Novel circulating biomarker digital scores for assessing treatment response in liver cancerR21CA280444 · NCI · CEDARS-SINAI MEDICAL CENTER · PI YANG, JU DONG, ZHU, YAZHEN · 2023 to 2023
$436k
NCI NIH HHS K08 CA259534NCI NIH HHS R01 CA246304NCI NIH HHS R01 CA253651NCI NIH HHS R01 CA255727NCI NIH HHS R01 CA277530NCI NIH HHS R21 CA280444NCI NIH HHS R44 CA288163NCI NIH HHS U01 CA230705NCI NIH HHS U01 CA271887NIBIB NIH HHS U01 EB026421NIH HHS K08CA259534NIH HHS R01CA246304NIH HHS R01CA253651NIH HHS R01CA253651-04S1NIH HHS R01CA255727NIH HHS R01CA277530NIH HHS R21CA280444NIH HHS R44CA288163NIH HHS U01CA230705NIH HHS U01CA271887NIH HHS U01EB026421
6 · The paper itself

Abstract

Alzheimer's disease (AD), the most prevalent type of dementia, is characterized by a biological process that begins with the development of AD neuropathologic change (ADNPC) while individuals remain asymptomatic. A key molecular hallmark of ADNPC is the accumulation of amyloid-β plaques. β-secretase plays a critical role in the upstream pathological cleavage of amyloid precursor protein (APP), producing amyloid-β peptides that are prone to misfolding, ultimately contributing to plaque formation. Neuronal extracellular vesicles (NEVs) in the blood transport β-secretase and preserve its activity, allowing for noninvasive profiling of β-secretase activity for detecting early onset of ADNPC. In this study, a novel approach is approached for noninvasive assessment of β-secretase activity in AD patients using an NEV β-secretase activity assay. This assay identifies NEVs exhibiting colocalization of NEV markers with AD-associated β-secretase, generating a β-secretase activity profile for each patient. The NEV β-secretase activity assay represents a significant advancement in leveraging the diagnostic potential of NEVs, offering a noninvasive, quantitative method for reliably assessing β-secretase activity to detect the early onset of ADNPC.

Indexed as

Alzheimer DiseaseAmyloid Precursor Protein SecretasesClick ChemistryExtracellular VesiclesNeuronsAgedAmyloid beta-PeptidesBiomarkersFemaleHumansMaleAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesBiomarkersAlzheimer's diseaseliquid biopsyneurodegenerative diseaseneuronal extracellular vesicleβ‐secretase

Identifiers

PMID40245252
PMCPMC12245089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.